Top Health Tech Companies in Chicago, IL (508)

Strong Revenue Growth: Revenue expanded rapidly, with FY2025 up 83% to about $1.27B and Q1/Q2 2026 up 36% and 22% year over year, respectively. Management also raised 2026 revenue guidance to approximately $1.595–$1.605B.

Diversified Revenue Streams: Both Diagnostics and Data & Applications are expanding, with Diagnostics up 34.7% in Q1 and 20% in Q2 2026 and Insights/data licensing up 36% in Q2 alongside about $200M in new licenses. Rising oncology test volumes (28–31% YoY) and accelerating MRD tests (~4,700 in Q4 2025 to ~9,000 in Q2 2026) reinforce multiple growth engines.

Profitability: The company achieved its first GAAP-profitable quarter in Q2 2026 (net income about $5.6M; Adjusted EBITDA ~$8.0M). Guidance points to further improvement in 2026, indicating progress toward sustained profitability.

Strategic Partnerships: The acquisition by Model N positions Kalderos’s 340B and gross-to-net capabilities inside a larger life-sciences revenue platform, implying broader distribution and customer access. Integration of the Truzo claims-level visibility into Model N’s suite signals strategic value and scale-up potential.

Strong Revenue Growth: Company materials state revenue more than doubled two years in a row leading into 2023, alongside expanding customers and team. These signals point to strong pre-acquisition traction that can be leveraged under Model N.

Market Expansion: 340B drug purchases reached roughly $66.3B in 2023, indicating a large and expanding market the combined offering serves. This category tailwind supports ongoing demand for discount-management and gross-to-net solutions.

Market Expansion: Headcount and footprint are described as rising to more than 15,000 employees across 40-plus offices, alongside concrete new sites in Hyderabad and a completed Chicago buildout—signals of geographic and capacity expansion. These moves indicate confidence in demand across key delivery hubs.

Innovation-Driven Growth: A dedicated Platforms & Products unit, the ZAIDYN portfolio, and AI-agent initiatives point to sustained investment in productized, AI-enabled offerings. Capability-deepening acquisitions (Digital Additive in 2024 and Torrent Consulting in 2025) further strengthen CRM and multi‑cloud life‑sciences solutions.

Strategic Partnerships: An expanded Salesforce collaboration around Agentforce and recognition as Databricks 2025 Life Sciences Partner of the Year suggest momentum in data/AI ecosystems. These alliances position the firm to capture spend where CRM, data, and AI converge in healthcare and life sciences.

Investor Backing & Capital Strength: Large late-stage financing and valuation momentum signal strong access to capital, including a $250M Series E and corroborated unicorn-scale valuations. Capital depth is further reinforced by indications of continued fundraising interest.

Strategic Partnerships: Embedded distribution with Zillow Rentals’ AI Assist, powered by EliseAI, is reported to drive higher renter engagement and application behavior. Such channel access expands reach and evidences measurable impact in real-world funnels.

Strong Revenue Growth: Company disclosures indicate surpassing $200M in ARR with continued acceleration from earlier milestones. Adoption signals across large operators align with sustained top-line expansion.

Investor Backing & Capital Strength: Advent International agreed on August 25, 2025 to acquire PatientPoint, with reporting at more than $1.4B, providing external validation and resources to accelerate expansion. This backing is positioned to support network growth and product innovation.

Product Line Growth: In March 2026 PatientPoint launched programmatic buying (Health Audiences) and a Consumer Health Network aimed at CPG/OTC brands, expanding how advertisers can buy and who the company serves. These additions broaden monetization beyond traditional life‑sciences sponsors.

Strong Market Position & Advantage: PatientPoint reports a nationwide footprint in 30,000+ physician offices and 125,000 providers, and in April 2026 received expanded Media Rating Council accreditation across its full digital screen network. This scale and third‑party validation bolster credibility for national buys.

Diversified Customer Base: Company materials indicate Strata now serves more than 2,300 organizations across healthcare, higher education, and financial services, with recent moves extending further into financial institutions. The Syntellis combination and the 2026 c. myers acquisition broaden exposure beyond hospitals, diversifying growth drivers.

Product Line Growth: New offerings such as StrataJazz Position Control (June 2025) and AI-driven Predictive Analytics (March 2026) expand the platform’s capabilities. These launches address labor optimization and earlier financial risk detection, signaling continued investment in the product suite.

Strategic Partnerships: A March 2025 collaboration with Snowflake is aimed at handling explosive growth in customer data needs and scaling a large comparable healthcare financial dataset. This alignment supports platform performance and data accessibility as the customer base grows.

Product Line Growth: Product breadth is expanding with the launch of ALIS 500 benchmarking and the AI assistant “Ask ALIS,” alongside ongoing UX/navigation enhancements in limited release. These moves indicate continued investment in data products and core platform capabilities.

Strategic Partnerships: Partnerships are deepening through new bidirectional integrations such as Inspiren (AI fall detection), Sunbound (payments), and CCN Health (contactless vitals), signaling a growing ecosystem. These additions point to stronger enterprise pull and a more connected operating environment.

Market Expansion: Market presence is rising as the company hosts the ALIS FWD conference and maintains a dense Fall 2026 conference schedule, reflecting stepped‑up marketing and sales activity. Hiring signals and listed openings suggest capacity building to support broader go‑to‑market reach.

Innovation-Driven Growth: Regulatory momentum is evident with FDA 510(k) clearance for the eVO2peak Module and references to multiple FDA-cleared algorithms, alongside ISO 13485 and MDSAP certifications. Ongoing clinical activity and datasets (e.g., OCORO Heart Study, multi‑million hours of heart data) point to a steadily expanding product and evidence base.

Strategic Partnerships: The March 27, 2025 acquisition by Kardigan integrates Prolaio’s FDA‑cleared software, curated CV datasets, and analytics into a larger R&D platform, signaling added resources and scope. Materials indicate Prolaio continues operating independently while benefiting from Kardigan’s broader heart‑health strategy.

Strong Hiring & Retention: Hiring signals are visible through an active careers page, a stated 32 new hires in 2025, and multiple current openings across functions. Employer recognition such as “Best Places to Work 2026” and ongoing recruiting activity suggest team expansion and brand momentum.

Strong Market Position & Advantage: Industry materials describe Owens & Minor P&HS as a leading national med‑surg distributor with extensive distribution and manufacturing reach, while Accendra’s Apria and Byram operate at national scale in home‑based care. Recognition from major GPOs signals credibility with large health systems.

Strategic Partnerships: National arrangements such as selection for a preferred DME network and supplier performance awards from Vizient indicate strong channel access. These relationships support volume and reinforce account stickiness with large IDN/GPO customers.

Future-Ready Strategy: Management has repositioned the public company as a pure‑play home‑based care platform and initiated a balance‑sheet optimization to support execution. Maintaining 2026 guidance amid the transition suggests planned continuity while the reset proceeds.

Strong Revenue Growth: Operating revenue grew from about $15.9 billion in 2024 to roughly $18 billion in 2025 alongside an operating margin above 4%. Patient encounters also reached a record, rising from about 15.7 million in 2024 to nearly 16 million in 2025.

Market Expansion: The system is adding capacity across geographies, including a $340 million expansion in Avon, a planned private cancer hospital in London by 2027, and continued growth at Cleveland Clinic Abu Dhabi. Scale includes 23 hospitals and 280 outpatient locations as of year‑end 2024, with rising international patient volumes.

Strong Brand Reputation: Global and national rankings place the organization among the top hospitals, including Newsweek’s No. 2 worldwide ranking and continued U.S. News Honor Roll status in 2025–2026. Specialty depth remains broad, with numerous top national placements and No. 1 in Ohio.

Strong Market Position & Advantage: Komodo is positioned as a top-tier U.S. real‑world data and patient‑journey analytics platform with a large longitudinal “Healthcare Map” covering 330M+ de‑identified patients, supporting life‑sciences use cases at scale.

Strategic Partnerships: Ecosystem moves and partnerships—such as recognition by Databricks, availability via AWS Marketplace, and data collaborations (e.g., GeneDx, Nasdaq)—signal strong distribution leverage and expanding data/network effects.

Product Line Growth: Komodo has expanded beyond data into packaged applications and an AI layer (e.g., MapLab, MapView, and Marmot), indicating continued productization to shorten time‑to‑insight and broaden workflows served.